CTOs on the Move

Signature Family Wealth

www.signaturefamilywealth.com

 
Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

California Choice

California Choice is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TriStar StoneCrest Medical Center

StoneCrest Medical Center offers acute care services including emergency and intensive care, general surgery, cardiology, obstetrics, physical medicine, outpatient diagnostic services and cancer care. From the newest in cardiac ultrasound technology to the state-of-the-art catheterization lab, TriStar StoneCrest is equipped to deliver a range of services to help prevent, treat, and recover from heart disease and stroke. From screenings to diagnostic cardiac catheterization, from angioplasty to rehabilitation, TriStar StoneCrest`s services have earned a reputation for excellence.

Storandt Pann Margolis

Storandt Pann Margolis is a La Grange, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vascular and Interventional Physicians

Doctors Imaging Group provides coverage at the Diagnostic Imaging Center, North Florida Regional Medical Center and our satellite offices at West, East, and Palatka locations. At each of these centers our goal is two-fold.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.